Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK...
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical...
Posts about
Success Stories
Veristat Congratulates Origin Biosciences for FDA Approval
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021
Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a...
Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19
In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...
Veristat Supports Antibe Therapeutics for Pain and Inflammation Study
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B...
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies...
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That...
Veristat Recognized for a Third Consecutive Year on the Inc. 5000 List of America’s...
Veristat’s Growth Positively Impacts Our Ability to Help Clients Achieve Regulatory Approval of their Life-Changing and Life-Saving Therapies
Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending...
SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome,
Veristat Congratulates TESARO on the FDA Approval of ZEJULA™
SOUTHBOROUGH, MA – May 30, 2017 – Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the...